ACIP recommends Flublok flu vaccine for adults with egg allergies

Protein Sciences Corporation, a vaccine development company, announced on Friday that the Advisory Committee on Immunization Practices passed a measure to recommend the use of Flublok influenza vaccine for adults with an egg allergy.

The Meriden, Conn.-based Protein Sciences said the unanimous 13-0 vote to recommend the vaccine for adults between the ages of 18 and 49 showed unprecedented support by the ACIP. The advisory committee advises the U.S. Centers for Disease Control and Prevention.

Protein Sciences does not use eggs in any part of the manufacturing process for Flublok.

"We are grateful to receive ACIP's unanimous support," Manon Cox, the president and CEO of Protein Sciences, said. "It is wonderful that we are able provide a solution to those egg allergic individuals who have never felt comfortable getting a flu vaccine."

On January 16, the U.S. Food and Drug Administration approved Flublok, a recombinant protein-based vaccine for the prevention of seasonal influenza disease. The vaccine employs modern cell culture technology and does not contain any preservatives, latex or egg proteins. Flublok also contains three times the active ingredient of traditional flu vaccines.

The ACIP is composed of 15 experts selected by the Secretary of the U.S. Department of Health and Human Services. The committee develops recommendations on how to use vaccines for disease control in the U.S.